KuDOS Pharmaceuticals

KuDOS Pharmaceuticals was one of our spinouts and was based upon the science of DNA damage sensing, signaling and repair to address unmet medical needs in cancer treatment. It was successfully exited and was acquired by AstraZeneca in 2006 for $210M.

Case study:¬†Olparib (Lynparza¬ģ): PARP inhibitors: Halting cancer by halting DNA repair